<DOC>
	<DOCNO>NCT00563368</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy various dose VI-0521 compare placebo , single-agent component comprise combination dose . This study provide confirmatory data demonstrate dose VI-0521 efficacy great placebo single-agent component comprise combination dose .</brief_summary>
	<brief_title>A Study Comparing Multiple Doses VI-0521 With Placebo Their Single-agent Constituents Treatment Obesity Adults</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>70 year age less body mass index ( BMI ) 30 45 kg/m2 Informed Consent Females childbearing potential must use adequate contraception Stroke/myocardial infarction ( MI ) /unstable cardiovascular disease within 6 month Clinically significant renal , hepatic psychiatric disease Unstable thyroid disease replacement therapy Nephrolithiasis Obesity know genetic endocrine origin Participation formal weight loss program lifestyle intervention Glaucoma elevate intraocular pressure Pregnancy breastfeed Drug Alcohol abuse Smoking cessation within previous 3 month plan quit smoke study Eating disorder within past year Cholelithiasis within past 6 month Type 2 diabetes Previous bariatric surgery Bipolar disorder psychosis Steroid hormone therapy stable 3 month Systolic blood pressure &gt; 160 mmHg , diastolic blood pressure &gt; 100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>